TORONTO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced today that its Board of Directors has established October 27, 2025 as the record date for the distribution of contingent value rights ("CVRs") to holders of its Class B Subordinate Voting Shares on a one-for-one basis, advancing the Company's previously disclosed plan in the Company's press release dated June 13, 2025, to deliver a litigation-linked CVR to shareholders of record as of the record date.

Each CVR will entitle the holder to receive a pro rata portion of a minimum of 10% and up to 50% of the net proceeds ultimately recovered by the Company in connection with its legal action against CIBC World Markets, RBC Dominion Securities, and others, which alleges stock price manipulation and spoofing and seeks damages in excess of USD $700 million (the "Litigation"). No payment will occur under the CVRs unless and until the Company receives net proceeds from the Litigation following a settlement or a final, non-appealable judgment ("Qualifying Net Proceeds"). There is no guarantee that any net proceeds will be received or that any payment will be made under the CVRs, as a result of the Litigation.

The CVRs:

Will not be listed on any exchange or marketplace;

Will be non-transferable and non-assignable;

Will not carry interest or voting rights;

Will be redeemable only for cash, and only in the event that the Company receives net proceeds from the resolution of the Litigation (whether by settlement or final judgment).

"This record date is a key milestone in aligning potential future recoveries from the Company's Litigation directly with our shareholders through a simple and enforceable right that pays only if value is realized," said Zeeshan Saeed, Founder, CEO and Executive Co-Chairman ...